Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Expands By 31.0%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 14,800 shares, a growth of 31.0% from the February 28th total of 11,300 shares. Based on an average trading volume of 34,700 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for approximately 0.0% of Gilead Sciences Inc.’s portfolio, making the stock its 14th biggest position. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. 25.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Barinthus Biotherapeutics in a report on Friday, March 21st.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ BRNS traded down $0.08 during mid-day trading on Monday, hitting $0.97. 3,668 shares of the stock traded hands, compared to its average volume of 33,322. The company has a market cap of $39.10 million, a PE ratio of -0.65 and a beta of -0.80. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16. The firm has a 50 day simple moving average of $1.02 and a two-hundred day simple moving average of $1.11.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Thursday, March 20th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $14.97 million during the quarter. On average, equities research analysts anticipate that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.